$SESN News
Last published 3y ago
- 3y agoJPMMOMOLCIDBLK+14Stocks making the biggest moves before the bell: JPMorgan Chase, Wells Fargo, PNC, Lucid, Express & moreCNBCThese are the stocks posting the largest moves in premarket trading.
- 3y agoSESNSesen Bio Stockholders Approve Merger with Carisma TherapeuticsBusiness WireDeclares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or
- 3y agoSESNSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsBusiness WireSesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders
- 3y agoSESNLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaBusiness WirePositive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR"
- 3y agoSESNLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote "FOR" All Proposals at March 2 Special MeetingBusiness WireReport Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger
- 3y agoSESNSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerBusiness WireSesen Bio, Inc. (NASDAQ:SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. ("Carisma") management team on Tuesday, February 21, 2023, at
- 3y agoSESNBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsBusiness WireSesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" the Value Maximizing Merger on the WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that BML
- 3y agoSESNSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerBusiness WireAmend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027 Bradley L. Radoff and Michael Torok to Vote Shares in Support of
- 3y agoSESNSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerBusiness WireHighlights Board's Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders Urges Stockholders to Vote "FOR" Transaction Ahead of Special Meeting of Stockholders
- 3y agoSESNSesen Bio Receives NASDAQ Delisting NoticeBusiness WireCompany Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution if Merger is not Approved by Stockholders Sesen Bio, Inc. (NASDAQ:SESN)
- 3y agoSESNSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersBusiness WireCompany Calls Out Misrepresentations from Investor Group Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma
- 3y agoSESNInvestor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger SupportBusiness WireDiscloses Recent Offer to Provide Paid Advisory Roles to Messrs. Radoff and Torok – Major Stockholders of Sesen Bio – in Exchange for Their Support of the Proposed Merger of Sesen Bio and Carisma Reiterates Intent to
- 3y agoSESNSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsBusiness WireSchedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com, Providing Additional Information for Stockholders Sesen Bio, Inc. (NASDAQ:SESN) today announced that it
- 3y agoSESNInvestor Group Issues Letter to Sesen Bio's Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerBusiness WireCalls on Board to Stop Wasting Corporate Resources and Hold a Stockholder Vote as Soon as Possible Questions the Board's Apparent Desire to Keep Stockholders in the Dark on Key Details Bradley L. Radoff and Michael
- 3y agoSESNSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsBusiness WireHighlights Expected Special Cash Dividend of Approximately $70 Million, and Upside of CVR and Ownership of Combined Company Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's
- 3y agoSESNInvestor Group Reiterates Intent to Vote AGAINST Sesen Bio's Value-Destructive Merger with CarismaBusiness WireProposes Alternative to the Merger That Would Deliver Superior Value for Sesen Bio's Stockholders Questions the Sesen Bio Board's Resistance to Obtaining a New Fairness Opinion for Carisma Now That Comparable Companies
- 3y agoSESNSesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending MergerBusiness WireSesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend, an Increase from up to $25 Million Previously Announced Contingent Value Right to Include Proceeds of Vicineum and Other
- 4y agoSESNSesen Bio Reports Third Quarter 2022 Financial Results and Business UpdateBusiness WireSesen Bio announced proposed merger with Carisma Therapeutics
- 4y agoSESNSesen Bio and Carisma Therapeutics Announce Merger AgreementBusiness WireTransaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders Combined company expected to have approximately $180 million of cash, cash equivalents
- 4y agoSESNSesen Bio Reports Second Quarter 2022 Financial Results and Business UpdateBusiness WireCompany continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 Sesen Bio (NASDAQ:SESN) today
- 4y agoSESNSesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the USBusiness WireCompany intends to seek a partner for further development of Vicineum Sesen Bio continues to focus on the assessment of potential strategic alternatives Sesen Bio (NASDAQ:SESN) today announced that it has made the strategic decision to voluntarily
- 4y agoSESNSesen Bio Reports First Quarter 2022 Financial Results and Business UpdateBusiness WireStrong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022, expected to fund current operating plan into the fourth quarter of 2024 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein
- 4y agoAMCRAMRNFRSHIAG+1Thinking about buying stock in Amarin, Iamgold, Amcor, Freshworks, or Sesen Bio?PR NewswireNEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMRN, IAG, AMCR, FRSH, and SESN. To
- 4y agoBRQSENDPLCIDSESN+1Thinking about buying stock in Lucid Group, Sesen Bio, Borqs Technologies, Endo International, or Spero Therapeutics?PR NewswireNEW YORK, May 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, SESN, BRQS, ENDP, and SPRO. T
- 4y agoSESNSesen Bio Provides Strategic UpdateBusiness WireSesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizin
- 4y agoSESNSesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company's Lead Product Candidate, Vicineum™Business WireParticipated in productive CMC and Clinical Type A Meetings with the FDA in the fourth quarter Type C Meeting with the FDA planned for March 28, 2022 Strong balance sheet with $163M in cash and cash equivalents as of December 31, 2021 expected to
- 4y agoSESNSesen Bio Further Enhances Team with Key HiresBusiness WireMinori Rosales, M.D., Ph.D. Brings Over 15 Years of Clinical Experience Stephanie Vigue to Support Company's Mission with Broad Corporate Finance Expertise Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein t
- 4y agoIINNKGCOCGNSESN+1Thinking about buying stock in Inspira Technologies, Kinross Gold, Ocugen, Sesen Bio, or TAL Education?PR NewswireNEW YORK, Dec. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IINN, KGC, OCGN, SESN, and TAL. To
- 4y agoSESNSesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™Business WireCompany plans to conduct an additional clinical trial for potential resubmission of BLA Company expects to hold a Type C meeting with the FDA in early 2022 to discuss the clinical trial protocol Sesen Bio (NASDAQ:SESN), a late-stage clinical compa
- 4y agoSESNSesen Bio Strengthens Medical TeamBusiness WireSesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Direct
- 4y agoSESNSesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor RoleBusiness WireSesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio's Board of Directors and th
- 4y agoANVSCLAQUIMNMPAVM+222nd Century Group Announces CFO TransitionGlobeNewswireRichard Fitzgerald Joins as Chief Financial Officer John Franzino Transitions to Chief Administrative Officer BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company f
- 5y agoSESNSesen Bio Reports Third Quarter 2021 Financial Results and Business UpdateBusiness WireParticipated in productive CMC Type A Meeting with the FDA Maintained strong balance sheet with $175M in cash and cash equivalents as of September 30, 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein t
- 5y agoSESNSesen Bio Announces Productive CMC Type A Meeting with the FDABusiness WireVicineum™ manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patient
- 5y agoAMDAVDLBNTXSCCO+1Thinking about buying stock in Advanced Micro Devices, Avadel Pharmaceuticals, Southern Copper, Sesen Bio, or BioNTech?PR NewswireNEW YORK, Oct. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, AVDL, SCCO, SESN, and BNTX.
- 5y agoCYCNFINVICCMSESN+1Thinking about buying stock in Sesen Bio, FinVolution Group, Valneva SE, Cyclerion Therapeutics, or Icecure Medical?PR NewswireNEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SESN, FINV, VALN, CYCN, and ICCM.
- 5y agoCRXTJNJONCYORPH+1Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming PeersPR NewswireVANCOUVER, BC, Oct. 14, 2021 /PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing even better with 14.7% and 12.1% gains respectively, th
- 5y agoSESNSesen Bio Expands CMC and Clinical TeamsBusiness WireSesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its chemistry, manufacturing, and control (CMC) and clinical development t
- 5y agoADTXEDUNAKDSESN+1Thinking about buying stock in Sundial Growers, Naked Brand, New Oriental Education, Aditxt, or Sesen Bio?PR NewswireNEW YORK, Aug. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, NAKD, EDU, ADTX, and SESN. T
- 5y agoABVCCASIQBIOSESN+1Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026PR NewswirePALM BEACH, Fla., Aug. 24, 2021 /PRNewswire/ -- Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous diseases have developed in the
- 5y agoSESNLost Money in Sesen Bio, Inc.?Business WireGibbs Law Group Investigates Potential Securities Law Violations Sesen Bio, Inc. shares plummeted after a STAT News report claimed the FDA's recent rejection of the company's clinical trial for its drug Vicineum was due to "thousands of violations of
- 5y agoSESNLost Money in Sesen Bio, Inc.?Business WireGibbs Law Group Investigates Potential Securities Law Violations Sesen Bio, Inc. shares dropped 13% on Wednesday, August 18, 2021 after a STAT News report claimed the FDA's recent rejection of the company's clinical trial for its drug Vicineum was du
- 5y agoEDUFNAOVSESN+1Thinking about buying stock in Sesen Bio, NanoVibronix, Tencent Music Entertainment, New Oriental Education, or Ford Motor?PR NewswireNEW YORK, Aug. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SESN, NAOV, TME, EDU, and F. To se
- 5y agoSESNFederman & Sherwood Announces an Investigation into Sesen BioBusiness WireFederman & Sherwood announces an investigation into Sesen Bio (NASDAQ:SESN). The complaint will allege violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuin
- 5y agoAQBCTICGRUBHSDT+1Thinking about buying stock in Helius Medical Technologies, Sesen Bio, Aquabounty Technologies, Just Eat Takeaway, or CTI BioPharma?PR NewswireNEW YORK, Aug. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HSDT, SESN, AQB, GRUB, and CTIC. T
- 5y agoBIOLFLGCMFCPSFE+1Thinking about buying stock in Sesen Bio, Paysafe, Manulife Financial, Flora Growth, or Biolase?PR NewswireNEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SESN, PSFE, MFC, FLGC, and BIOL. T
- 5y agoSESNSesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)Business WireCompany to host conference call on Monday, August 16 at 8:00 a.m. ET Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it received a
- 5y agoAEMDBOXLCODXPPC+1Thinking about buying stock in Boxlight, Pilgrim's Pride, Co-Diagnostics, Sesen Bio, or Aethlon Medical?PR NewswireNEW YORK, Aug. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BOXL, PPC, CODX, SESN, and AEMD. T
- 5y agoSESNSesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™Business WireJohn Knighton to join Sesen Bio as Vice President and Chief Compliance Officer The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developin
- 5y agoSESNSesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™Business WireThe Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 The Company also believes it remains on track for potential approval in Europe and key markets in MENA in 2022 Strengthened balance sheet with